Physician profile
Ramon A Solis
NPI 1427058171
$5,373.45
in general payments reported to CMS, 2019-2025
43 companies · $469 in 2025
The $469 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,123 · 2020: $438 · 2021: $857 · 2022: $955 · 2023: $852 · 2024: $679 · 2025: $469.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,001.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,000.63 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,425.74 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $568.51 | 2019-2024 | Farxiga, Breztri |
| Janssen Pharmaceuticals, INC | $365.52 | 2019-2022 | |
| Amgen INC. | $296.07 | 2019-2025 | Repatha, Otezla, Repatha |
| Astellas Pharma US INC | $227.55 | 2019-2025 | Veozah, Myrbetriq |
| Boehringer Ingelheim Pharmaceuticals, INC. | $219.05 | 2019-2025 | Jardiance, Synjardy |
| Lilly USA, LLC | $215.34 | 2019-2025 | Jardiance, Mounjaro, Emgality |
| Novartis Pharmaceuticals Corporation | $205.20 | 2023-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $187.09 | 2021-2025 | |
| Glaxosmithkline, LLC. | $161.75 | 2019-2024 | Shingrix, Arexvy, Trelegy Ellipta |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $156.51 | 2019-2025 | Xifaxan, Trulance |
| Abbott Laboratories | $147.91 | 2019-2023 | Eterna, Prodigy |
| Pfizer INC. | $147.79 | 2021-2025 | |
| Merck Sharp & Dohme LLC | $143.80 | 2019-2023 | Gardasil 9, Pneumovax 23, Vaxneuvance |
| Mannkind Corporation | $128.67 | 2019-2020 |
Show all 43 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ramon Solis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.